SIRT3 ameliorates osteoarthritis via regulating chondrocyte autophagy and apoptosis through the PI3K/Akt/mTOR pathway

Kai Xu1, Yuzhe He1, Safwat Adel Abdo Moqbel1

  • 1Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Insights

Sirtuin 3 (SIRT3) protects against osteoarthritis (OA) by reducing inflammation and cell damage. Overexpressing SIRT3 in rats alleviated joint damage, highlighting its therapeutic potential for this common joint disease.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pathology

Background:

  • Osteoarthritis (OA) is a prevalent degenerative joint disease.
  • Understanding molecular mechanisms underlying OA is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of Sirtuin 3 (SIRT3) in osteoarthritis (OA) pathophysiology.
  • To elucidate the underlying molecular mechanisms of SIRT3's function in OA.

Main Methods:

  • Utilized rat chondrocytes and a destabilized medial meniscus (DMM) rat model for in vitro and in vivo studies.
  • Employed lentivirus and plasmid for SIRT3 overexpression and siRNA for SIRT3 knockdown.
  • Administered intra-articular SIRT3 overexpression in a rat OA model.

Main Results:

  • SIRT3 overexpression inhibited IL-1β-induced inflammation, apoptosis, mitochondrial dysfunction, and chondrocyte degeneration.
  • SIRT3 overexpression restored IL-1β-induced autophagy inhibition and suppressed PI3K/Akt/mTOR signaling.
  • Intra-articular SIRT3 overexpression reduced the severity of OA-induced joint damage in rats.

Conclusions:

  • SIRT3 acts as a protective factor against osteoarthritis.
  • SIRT3 exerts its protective effects by inhibiting the PI3K/Akt/mTOR signaling pathway.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K